Amphion Innovations Share Discussion Threads

[pilkersa] 06/1/2015 22:08

With respect ARMS are chasing money from a guy who is highly unlikely to pay with only a couple of chateaus worth less than a nice Mayfair flat being seized as collateral. I am not invested here but nonetheless it seems an entirely different proposition.

[petersmith6] 06/1/2015 22:05

So 10p with a reality spin

[petersmith6] 06/1/2015 22:02

So 20p conservative.

[21trader] 06/1/2015 22:02

jumbone

Think ISIS has a point you need some numbers but I can understand the excitement of a court win over patent infringement it opens doors for all others to settle.

But I reckon easily 95% of spikes do not hold the gains so it will take something special to rise in the morning and hold it. ARMS closed at 26p after their spike
opened the same hit 31p held the gains for 2 hours then tanked to 18p now 10p.
I do think AMP will rise in the opening minutes because it closed at the intraday high but after 8.10am they usually come back sharply.

Need a crystal ball.

[isis] 06/1/2015 21:59

And where has that money gone?

They have had to issue more shares and sell off Kromek.

Seems to be a bottomless pit this Company and their stakes get smaller and smaller.

[jumbone] 06/1/2015 21:57

ISIS:

DataTern Earned more than 40 mill USD in 2012 from some of the companies that agreed to pay the licence fees.

That does not include MSFT & SAP & many Biggies....

So you put a number in GB Pounds...

Then divide it by 148,278,506

Then multiply it by 100

The reslt is the number of PENCE the share price should be just from "Patent Infringement"

[euclid5] 06/1/2015 21:53

any conservative idea of the amount they will get from these co's & the time frame to be paid could we be looking at years away or just months away?

[jumbone] 06/1/2015 21:53

21 Trader:

So you agree that this is going places tomorrow and there after then..?

[isis] 06/1/2015 21:52

We need to see some figures really and there aren't any except Pie in the Sky investors ones.

Same was said about the other Companies in AMP - noone have done much except burn large amounts of cash.

[euclid5] 06/1/2015 21:51

Excellent post Jumbone - thank you

[21trader] 06/1/2015 21:48

Patent infringement was my biggest winner in 20 years of trading when Rodime
took on Seagate over 10 years+ but finally Seagate had to settle they knew they
would lose. Price went from low of 1p to high of 40p aided by Dot Com boom but on the court win news they went from 1.5p to 12p in 2 days.

[jumbone] 06/1/2015 21:35

A lot of the posts here seem to have no understanding of what the REAL ISSUE here is

This share price rise is not to do with the AMP's business model, NAV, or other partner companies.

The CRUX of the issue is the US Federal Circuit Court Ruling on Patent Infringement

The Crux of the issue is in how much does DataTern a 100% AMP owned company is about to gain as it's share of licencing fees from HUNDREDS of Software development companies including Microsoft, IBM, Oracle, SAP, Sybase, MicroStrategy and many many others.

Whatever are the licensing fees they are to be shared between DataTern & Firestar Software -where Amphion hold a 15.32% interest

The bone of contention is an U.S. Patent No. 6,101,502

This patent's titled is "Object model mapping and runtime engine for employing relational database with object oriented software"

This patent in full can be read at

This patent is Cited by citations in 10 Other patents

This patent is also Referenced Cited by citations in 70 Other patents

So this is a very important patent

This Patent's Advantage in a layman's language are--

1. People were trying to solve the problems of allowing Object oriented applications to seamlessly connected with and integrate with Relational databases.

2. The world is full of object oriented applications such as media files and complex data sets.

3. But the Data Base technologies is primitive and has remained on relational databases as spreadsheet in other words rows and columns

4. It was quite a daunting task to put real world objects in a relational databases in rows and columns

5. The solution was invented was a Mapping tool which allowed/ facilitated the automatic integration / mapping of object oriented applications into relational databases and vice versa

6. This enabled the two technologies to coexist and function effectively together

7. Based on that origin the patents were filed on the basis of two critical inventions that enabled this mapping

There were HUNDREDS of application developers developing objects and tools based on this technology without paying the licence fees to DataTern

Most of these were well funded Internationally renouned MNCs including Microsoft, SAP, Oracle, SUN, LINUX, SYBASE, and many more.

INSTEAD OF CONTESTING EACH OF THOSE INFRINGING COMPANIES DATATERN/ AMP CHOSE TO INSIS ON SEEKING A LICENCE FEE FOR USING THEIR INVENTION

DataTern sent the customers claim charts alleging infringement based on customers’ use of Microsoft’s ADO.NET and SAP’s BusinessObjects software

They obtained a revenue of more than $ 40 mill in 2012, from over 40 companies.

Some customers of Microsoft and SAP sought indemnification.

Microsoft told DataTern that Microsoft had no obligation to defend or indemnify its customers.

DataTern indicated that it was not interested in suing Microsoft or SAP but needed to be compensated for the utilization of their inventions

Microsoft & SAP then filed a case against DataTern in NewYork seeking declaratory judgments of noninfringement and invalidity

In addition they sought a covenent from DataTern not to sue the user companies of Microsoft’s ADO.NET and SAP’s BusinessObjects software

DataTern chose to fight this case and refused to grant a covenant not to sue the user companies

DataTern's appeal was based on two different issues.

1. That the New York court lacked jurisdiction and

2. That the Markman claim construction rendered on DataTern's patents was flawed.

DataTern won the FIRST Issue on the jurisdiction on 14-Apr-14

Due to the laws of patent infringement there were 20 companies in litigation on patent infringement in 3 different states of USA New York, Texas and massachusetts

One of those chose to compromise and there are 19 remaining contestents

DataTern Now has won on the SECOND and more important issue of Claim Construction in Texas against MicroStrategy + 7 others

This has just opened the PANDORA's BOX

This patent's validity is till 2017

Since almost every single big & medium sige software company is involved in this infringement they are all going to settle and settle soon

This licencing revenue is going to be many many folds of AMP's assets in other partner companies

[isis] 06/1/2015 21:34

It seems a bit odd that a tiny Company that AMP are invested in are the only ones in the World that are looking at Antibiotics that might cure MRSA?

WTF do Glaxo and all the others do with their Billions then??

lol

[petersmith6] 06/1/2015 21:27

H20water need to meet my friend..dihyrogen nomoxide

[21trader] 06/1/2015 21:26

isis

Best to ignore/filter sraynot.

The other day JQW was the share of 2015 something else will be by Friday.

JQW - In second place to $100 billion Alibaba. - JQW

smraynot - 04 Jan 2015 - 09:44:39 - 3132 of 3198
Good to see all the positives, and JQW being put forward as the share of 2015.

[isis] 06/1/2015 21:21

why?

perhaps you need to educate yourself.

[the stigologist] 06/1/2015 21:16

Unless you rowed for an Oxbridge 2nd XI you need to change your username mate

[isis] 06/1/2015 21:06

Where are your figures?

Kromek were supposed to have their products in all EU Airports two years ago and they have none there yet!

[smraynot] 06/1/2015 21:00

This really is going to be the share of 2015. My short term target is 20p+ with a realistic progression into the £'s

[isis] 06/1/2015 20:51

I've been following this stock for the past 5 years and there is always alot of Jam tommorrow stuff.
There are no figures with today's announcement - it has done this several times.

[mally6] 06/1/2015 20:49

falia
dont waste ur time on 21t and gang worst posters on board wait for a share to rise come on deramping with bullsh%it hoping to short.worst kind of posters no shame post rubbish

[h2owater] 06/1/2015 16:38

Amphion Partner, Motif, Poised to Help Solve Global Health Crisis

London and New York, 8 July 2014: Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, notes Prime Minister David Cameron’s 2 July 2014 statement pertaining to the launch of a new global taskforce, established to coordinate an international effort to combat antibiotic resistant superbugs. The taskforce, which is to be chaired by economist Jim O’Neill, will focus on how to find and develop new drugs, specifically antibiotics, in order to combat the ever-growing and serious problem of these antibiotic resistant superbugs.

Prime Minister David Cameron commented: “Resistance to antibiotics is now a very real and worrying threat as bacteria mutate to become immune to their effects. With some 25,000 people a year already dying of infections resistant to antibiotic drugs in Europe alone, this is not some distant threat but something happening right now. If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back to the dark ages of medicine where treatable infections and injuries can kill once again” - Source: 2 July 2014 Wellcome Trust Press Release

Amphion’s Partner Company, Motif BioSciences Ltd. (“Motif”), a cutting-edge drug discovery/development company based in New York City, has a stated mission to develop solutions addressing the antibiotic crisis. Motif is currently developing two new antibiotics that work in different ways to those commonly used today. In the opinion of the management team, no other company worldwide is currently developing antibiotics with the same mechanism. The highly experienced scientific team at Motif believes that these two new antibiotics will be particularly well equipped for commercial success. Motif’s target is to have two new antibiotics ready to launch to the healthcare market and the management team looks forward to providing an update on details and timing in due course.

Amphion’s Chief Executive Officer and Chairman of Motif, Richard Morgan, said: “We welcome the recent remarks made by Prime Minister Cameron regarding the antibiotic crisis and the initiatives he announced. With its leading team of experts, strategic partnerships, and new antibiotic candidates, Motif is poised to help address this situation.

“Amphion is currently the largest outside shareholder in Motif, which is second in size and importance in terms of our investment holdings. We look forward to seeing the company progress its development programmes and believe the upside potential to be very large if the company is successful.”